|Articles|April 27, 2018

Controversies in Urologic Cancer

How can you be sure you’ve selected the best approach for your patients with urologic cancer? As our experts debate developments like MRI fusion biopsy for PCa, HIFU for low-risk prostate cancer, and white light cystoscopy, learn how you can integrate these treatments into your practice.

Having trouble viewing? Click to downloadTrouble viewing this PDF?

Once you access the file, position your mouse over the top middle for a toolbar:

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Controversies in Urologic Cancer

Related Content

Point: Is MRI fusion biopsy the new gold standard for diagnosis?

Counterpoint: Is MRI fusion biopsy the new gold standard for diagnosis?

Point: Is HIFU for low-risk prostate Ca ready for prime time?

Counterpoint: Is HIFU for low-risk prostate Ca ready for prime time?

Point: Is stand-alone white light cystoscopy a thing of the past?

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Trending on Urology Times

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Doublet or triplet? Urologists weighs in on mCSPC options

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge